Picture BIO Deutschland Biotech Investors Day BID 2019 Würzburg 600x60px
Document › Details

Redx Pharma plc. (4/14/16). "Press Release: Board and Senior Management Changes".

Region Region Macclesfield, Cheshire
  Country United Kingdom (GB)
Organisations Organisation Redx Pharma plc (AIM: REDX)
  Group Redx Pharma (Group)
  Organisation 2 AstraZeneca plc (LSE: AZN)
  Group AstraZeneca (Group)
Products Product drug development
  Product 2 public relations / investor relations / marcom (services)
Persons Person Tottey, Philip (Redx Pharma 201601–201609 CFO LEFT 9/16)
  Person 2 Hård, Karl (Kiadis 201709– Head IR + Communications before Redx Pharma 201610– Head of IR + CorpComm before AstraZeneca)

Redx Pharma Plc announces that Phil Tottey, Chief Financial Officer, will be stepping down from the Board and leaving the Company on 30 September 2016 to pursue new opportunities. Andrew Booth, who is currently Financial Controller, will act as Interim Finance Director pending a permanent appointment.

At the same time, the Board is pleased to welcome Karl Hård to the Executive Management Team as Head of Investor Relations and Corporate Communications. Karl has spent almost 20 years at AstraZeneca PLC. Over the last nine years, he held senior roles within Investor Relations, latterly as Vice President. Before that, he worked as Global Programme Director, establishing new external collaborations, and as Director in Biological Chemistry, leading research into novel pharmacological targets. His scientific experience covers oncology, immunology and infection.

Karl was Assistant Professor in Chemistry at Leiden University, The Netherlands, and holds a PhD in Chemistry from Utrecht University, and an MSc in Biochemistry from Helsinki University, Finland.

Neil Murray, Chief Executive of Redx, commented: "On behalf of the Board, I would like to thank Phil for his significant contribution to Redx and particularly for his work during the Company’s IPO. We wish him well in his future endeavours."

"I am very pleased to welcome Karl Hård to Redx as Head of Investor Relations. His long career at AstraZeneca, which encompassed both scientific research and investor relations, means that he will be a valuable addition to the management team. We look forward to working with him as we drive forward Redx’s continuing development."

Record changed: 2017-05-26


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Redx Pharma (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture BIO Deutschland German Biotech Days 2019 Würzburg 600x60px

» top